Kanwal et al demonstrated that CD133‐positive prostate cancer cells were endowed with stem cell‐like characteristics, including therapeutic resistance to docetaxel, which is a chemotherapeutic drug acting efficiently on CD133‐negative prostate cancer cells.25 This evidence concerns the gene PROM1 and Familial prostate cancer.